Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Renal Cell 64Breast Neoplasms 20Kidney Neoplasms 19Gastrointestinal Stromal Tumors 16Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Neoplasm Metastasis 9Prostatic Neoplasms 8Urinary Bladder Neoplasms 7Brain Neoplasms 7Colorectal Neoplasms 6Neuroendocrine Tumors 5Carcinoma, Hepatocellular 5Carcinoma 5Thyroid Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Liver Neoplasms 4Thyroid Cancer, Papillary 3Sarcoma 3Pancreatic Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Kidney Diseases 3Glioblastoma 3Esophageal Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Astrocytoma 3Adenoma, Islet Cell 3Adenocarcinoma, Follicular 3

Interventions

Temozolomide 4Capecitabine 4Bevacizumab 3Leucovorin 2Fluorouracil 2Everolimus 2temsirolimus 1sapanisertib 1regorafenib 1pentetreotide 1pazopanib 1motesanib diphosphate 1irinotecan sucrosofate 1gallium Ga 68 dotatate 1dehydroftorafur 1batifiban 1aflibercept 1Sunitinib 1Sorafenib 1Sirolimus 1Panobinostat 1Oxaliplatin 1Octreotide 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Fentanyl 1Etoposide 1Doxorubicin 1Disulfides 1Cytidine Triphosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Somatostatinoma × Sunitinib × Clear all
NCT00428220 2019-06-27

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Pfizer

Phase NA Completed
223 enrolled 8 charts
BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Somatostatinoma, Thyroid Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡